Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0133 | 0 | 0.5 |
Echinococcus granulosus | dual specificity mitogen activated protein | 0.0368 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0133 | 0 | 0.5 |
Trypanosoma brucei | mitogen-activated protein kinase 3, putative | 0.0133 | 0 | 0.5 |
Loa Loa (eye worm) | STE/STE7/MEK3 protein kinase | 0.0368 | 1 | 1 |
Leishmania major | mitogen-activated protein kinase 3, putative,map kinase 3, putative | 0.0133 | 0 | 0.5 |
Echinococcus multilocularis | dual specificity mitogen activated protein | 0.0368 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 95 % | Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 12 to 28 days by L-J MIC method | ChEMBL. | No reference |
IZ (functional) | < 10 mm | Antimicrobial activity against Escherichia coli MTCC 739 assessed as diameter of growth inhibition zone after 24 hr | ChEMBL. | No reference |
IZ (functional) | = 12 mm | Antimicrobial activity against Candida albicans MTCC 183 assessed as diameter of growth inhibition zone after 48 hr | ChEMBL. | No reference |
MIC (functional) | = 100 ug ml-1 | Antimicrobial activity against Candida albicans MTCC 183 assessed as growth inhibition after 48 hr by agar streak dilution method | ChEMBL. | No reference |
MIC (functional) | = 100 ug ml-1 | Antimicrobial activity against Escherichia coli MTCC 739 assessed as growth inhibition after 24 hr by agar streak dilution method | ChEMBL. | No reference |
MIC (functional) | = 1000 ug ml-1 | Antituberculosis activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 12 to 28 days by L-J MIC method | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.